Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Barry Mangum"'
Autor:
Dotan Shaniv, Srinivas Bolisetty, Thomas E. Young, Barry Mangum, Sean Ainsworth, Linda Elbers, Petra Schultz, Melanie Cucchi, Saskia N. de Wildt, Tjitske M. van der Zanden, Neil Caldwell, Anne Smits, Karel Allegaert
Publikováno v:
Children, Vol 10, Iss 5, p 848 (2023)
Neonatal drug information (DI) is essential for safe and effective pharmacotherapy in (pre)term neonates. Such information is usually absent from drug labels, making formularies a crucial part of the neonatal clinician’s toolbox. Several formularie
Externí odkaz:
https://doaj.org/article/748400c3f75a4d199630b9ed7885fe85
Autor:
Allegaert, Dotan Shaniv, Srinivas Bolisetty, Thomas E. Young, Barry Mangum, Sean Ainsworth, Linda Elbers, Petra Schultz, Melanie Cucchi, Saskia N. de Wildt, Tjitske M. van der Zanden, Neil Caldwell, Anne Smits, Karel
Publikováno v:
Children; Volume 10; Issue 5; Pages: 848
Neonatal drug information (DI) is essential for safe and effective pharmacotherapy in (pre)term neonates. Such information is usually absent from drug labels, making formularies a crucial part of the neonatal clinician’s toolbox. Several formularie
Autor:
Thomas Salaets, Jonathan M. Davis, Michael D. Blum, Hidefumi Nakamura, Joseph G. Toerner, Susan McCune, Susan Tansey, Mary A Short, Ron Portman, Alexandra Mangili, Agnes Klein, Junko Sato, Barry Mangum, Laura Fabbri, Gerri Baer, Mark A. Turner, Isamu Hokuto, Karel Allegaert, Lynne Yao
Publikováno v:
Journal of Pediatrics, 219, 243-249. Mosby Inc.
ispartof: JOURNAL OF PEDIATRICS vol:219 pages:243-+ ispartof: location:United States status: published
Autor:
Nazila Salamat-Miller, Mark A. Turner, Amey Bandekar, Nitin Dixit, Emily Jochim, Barry Mangum, Christopher McPherson, Srini Tenjarla, Sukhjeet Singh, You Seok Hwang, Norman Barton
Publikováno v:
World journal of pediatrics : WJP.
Background Recombinant human (rh)IGF-1/IGFBP-3 protein complex, administered as a continuous intravenous infusion in preterm infants, is being studied for the prevention of complications of prematurity. Methods We conducted in vitro studies to evalua
Publikováno v:
Therapeutic innovationregulatory science. 47(5)
Trial simulations have emerged as a promising tool to optimize pediatric drug development programs. As the current FDA legislation on pediatric drugs and devices was updated to mirror the EMA legislation, pediatric programs must be developed with glo
Autor:
Ronit M. Pressler, Barry Mangum
Publikováno v:
Seminars in Fetal and Neonatal Medicine. 18:216-223
The treatment of neonatal seizures has not changed significantly over the last 50 years despite advances in antiepileptic drug (AED) development for older children and adults. Recently new drugs have emerged some of which address age-specific challen
Autor:
Shashidhar Kori, Pamela S Douglas, Donald J. Kellerman, Robert J. Noveck, Shein-Chung Chow, Barry Mangum
Publikováno v:
Drug Design, Development and Therapy
Robert J Noveck,1 Pamela S Douglas,2 Shein-Chung Chow,3 Barry Mangum,4 Shashidhar Kori,5 Donald J Kellerman51Duke Clinical Research Unit, Division of Clinical Pharmacology, Duke University School of Medicine, Durham, NC, USA; 2Imaging Program, Duke C
Autor:
William C. Wetsel, Tong H. Lee, Paolo Mannelli, Steven T. Szabo, Ashwin A. Patkar, O. Barry Mangum, J. Corey Fowler, Wayne F. Beyer
Publikováno v:
Drug and Alcohol Dependence. 124:11-18
Psychostimulant abuse continues to present legal, socioeconomic and medical challenges as a primary psychiatric disorder, and represents a significant comorbid factor in major psychiatric and medical illnesses. To date, monotherapeutic drug treatment
Autor:
Daniel K. Benjamin, Barry Mangum, Carissa M. Baker-Smith, Robert M. Califf, Henry G. Grabowski, Jessica Sun, Jennifer S. Li, Elizabeth D. Reid, Rex Edwards, Eric L. Eisenstein, M. Dianne Murphy, John V. Goldsmith
Publikováno v:
American Heart Journal. 156:682-688
Background Congress has authorized the United States Food and Drug Administration (FDA) to provide industry sponsors with a 6-month extension of drug marketing rights under the Pediatric Exclusivity Provision if FDA-requested pediatric drug trials ar
Autor:
Mona C. Toet, Vicki Livingstone, Ronit M. Pressler, Barry Mangum, Renate Swarte, Catherine Chiron, Neil Marlow, Sampsa Vanhatalo, Vincent Jullien, Mats Blennow, J. Helen Cross, Linda S. de Vries, Geraldine B. Boylan, Sarah Zohar, Brendan P. Murphy, Boubou Hallberg, Lena Hellström-Westas, Janet M. Rennie, Gérard Pons, Deirdre M. Murray
Publikováno v:
Lancet Neurology, 14(5), 469-477. Lancet Publishing Group
Lancet Neurology, 14(5), 469. Lancet Publishing Group
Lancet Neurology, 14(5), 469. Lancet Publishing Group
Summary Background Preclinical data suggest that the loop-diuretic bumetanide might be an effective treatment for neonatal seizures. We aimed to assess dose and feasibility of intravenous bumetanide as an add-on to phenobarbital for treatment of neon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0fa6dfcb17b8378b3635355e3309d96
https://dspace.library.uu.nl/handle/1874/333543
https://dspace.library.uu.nl/handle/1874/333543